DPDeepshikha Patle

Deepshikha Patle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Deepshikha Patle has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Structure–Activity and Stability Relationships of Guaiacol Derivatives as PPARγ Modulators: Insights from Molecular Dynamics and Electronic Structure Analysis

    by Deepshikha Patle, Rizwan Rahman Baruah, Dhamodharan Prabhu, Rakesh Chandra Kalita, Sachin Kumar Singh

  • Target‐Based Antitubercular Drug Discovery: Scaffold Diversity and SAR Trends of Small Molecules Against Mycobacterium Tuberculosis

    by Rakesh Chandra Kalita, Kaustubh Ajit Kolekar, Sachin Kumar Singh, Deepshikha Patle

    Tuberculosis remains a major infectious disease, and the increasing incidence of multidrug‐resistant Mycobacterium tuberculosis continues to limit current treatment options. This review summarizes recent medicinal chemistry efforts directed toward six important M. tuberculosis targets: InhA, DprE1, MmpL3, QcrB, DNA gyrase, and dihydrofolate reductase (DHFR). Emphasis is placed on the structural diversity and biological activity of potent molecules. SAR analysis relates changes in scaffold, substituent pattern, linker geometry, lipophilicity, and polarity to antimycobacterial potency and activity against resistant strains. Selected synthetic routes and clinically relevant antitubercular compounds are also discussed. Selected docking studies provide supportive structural information for representative potent inhibitors, while comparative SAR analysis provides an overview of the major structural features associated with activity across the target classes. Overall, the review summarizes recent medicinal chemistry advances in targeted antitubercular drug discovery and provides SAR considerations for further lead optimization.

  • Open Access

    Spirooxindole Derivatives as Emerging Scaffolds in Drug Discovery: Synthetic Strategies, Structure–Activity Relationship, and Biological Activities

    by Rakesh Chandra Kalita, Sarbanga Bezbaruah, Deepshikha Patle

    Spirooxindoles are a class of spirocyclic scaffolds in drug discovery, as the rigid frame and well‐defined substitution pattern can interact with various biological targets. Recent advances in synthetic methodologies, including multicomponent 1,3‐dipolar cycloadditions, organocatalytic cascades, and one‐pot protocols, have facilitated the efficient synthesis of a wide variety of derivatives for SAR studies. A diverse range of classes, including pyrrolidine, cyclopropyl carboxamide, carbamate, oxadiazoline, pyrrolizidine, and furan derivatives, show cytotoxicity in the submicromolar‐to‐low micromolar range with good selectivity. The SAR studies suggest that substitution on the isatin core generally enhances biological activity in individual series, especially with electron‐withdrawing groups, but these effects are scaffold dependent. Furthermore, spirooxindole derivatives have been reported to show antibacterial activity, including TrpRS inhibition, antimicrobial, acetylcholinesterase inhibition, α‐glucosidase inhibition, antiviral, and anticonvulsant activities. The recent patents, especially on MDM2 inhibitors and other anticancer agents with nanomolar potency, provide further evidence for the continued interest in spirooxindole‐based drug discovery. This review highlights the recent advancements in spirooxindole chemistry involving synthetic strategies, SAR, biological activities, and recent patents.

  • Walnut (Juglans regia L.) as a Promising Antidiabetic Agent: Mechanistic, Preclinical, and Clinical Evidence

    by Deepshikha Patle, Husam Najm A. Fazea

    Diabetes mellitus (DM) is a chronic metabolic disorder that continues to pose a major healthcare challenge worldwide. Despite the availability of several therapeutic options, achieving sustained glycaemic control and preventing long-term complications remain difficult in many patients. Walnut (Juglans regia L.) has gained attention as a potential complementary approach because of its diverse bioactive constituents and reported metabolic benefits. This review discusses the mechanistic, preclinical, and clinical evidence supporting the role of J. regia in diabetes management. The available studies indicate that walnut contains several phytochemicals, including juglone, flavonoids, polyphenols, and polyunsaturated fatty acids, which may contribute to antioxidant, anti-inflammatory, and insulin-sensitizing activities. Experimental findings suggest that these constituents help improve glucose homeostasis, protect pancreatic β-cells, and regulate insulin-signalling pathways. Preclinical studies consistently demonstrate beneficial effects on glycaemic parameters and pancreatic function, while clinical investigations report modest improvements in fasting blood glucose, HbA1c, and lipid profiles with good tolerability. However, differences in extract preparation, dosage, study design, and duration limit direct comparison among studies and highlight the need for further standardization. Future research should focus on well-designed clinical trials, optimized dosing strategies, and the evaluation of walnut preparations as adjuncts to conventional antidiabetic therapy. Overall, the current evidence supports J. regia as a promising complementary candidate for diabetes management and provides a basis for its further clinical development.

  • BOA and 6-MBOA (Coixol) Scaffolds: Synthetic Strategies, Potent Bioactive Derivatives, SAR, and Therapeutic Insights

    by Deepshikha Patle, Rakesh Chandra Kalita, Motamarri Venkata Naga Lalitha Chaitanya

    Benzoxazolinone (BOA) and its methoxy analogue, 6-MBOA (Coixol), are privileged heterocyclic scaffolds with diverse pharmacological potential, including neuroprotective, antidiabetic, anti-inflammatory, antimicrobial, and anticancer effects. BOA is a well-studied natural phytoconstituent with broad biological activity, whereas 6-MBOA has received comparatively less attention, despite its emerging biological relevance. The methoxy substitution at the 6-position of 6- MBOA modifies the electronic configuration, enhances lipophilicity, and improves metabolic stability, resulting in superior biological efficacy relative to its parent compound. Among the reported analogues, a benzoxazolinone-based autotaxin inhibitor (compound 26) demonstrated notable potency (IC₅₀;0.019 μM), and several triazole-linked or halogenated derivatives exhibited submicromolar anti-inflammatory and anticancer activities. This review consolidates current knowledge on BOA and 6-MBOA derivatives, focusing on structure-activity relationships, mechanistic underpinnings of bioactivity, and representative synthetic methodologies. Particular attention is given to patented compounds, emphasizing their therapeutic potential and structural innovation. Collectively, these insights establish BOA as a validated pharmacophoric scaffold and highlight 6-MBOA as a promising molecular framework for next-generation drug design and discovery.


  • Unveiling the Therapeutic Promise of Indole and Thiazole Derivatives in Treating Lung Diseases

    by Smriti Raj, Deepshikha Patle, Banoth Karan Kumar

    Heterocyclic scaffolds, particularly indole and thiazole compounds, are revolutionizing the treatment of lung diseases due to their structural diversity and broad therapeutic potential. Their ability to target multiple biological pathways positions them as powerful tools for developing innovative treatments for lung disorders, particularly lung cancer. This review systematically explores recent advances in the synthesis and biological evaluation of indole and thiazole derivatives, emphasizing detailed synthetic strategies and the identification of the most potent molecules reported in the studies referenced within this manuscript for their relevance to lung diseases, particularly lung cancer. The SAR studies elucidate the role of molecular features and key functional groups in enhancing the potency, selectivity, and therapeutic efficacy of synthetic indole and thiazole derivatives. Given that lung cancer remains the leading cause of cancer-related deaths worldwide, the findings highlight the urgent need for developing innovative and effective anti-lung cancer agents, with indole and thiazole scaffolds serving as promising therapeutic frameworks.


  • Narcotics through time: exploring historical origins, synthetic advances, and clinical progress

    by Rakesh Chandra Kalita, Shivank Sharma, Suman Samanta, Deepshikha Patle

    Pain management has remained one of the most critical challenges in clinical medicine over the past several decades, with narcotics continuing to play a central role in controlling moderate to severe pain. Originating from natural sources such as Papaver somniferum, these compounds have evolved significantly from plant-derived alkaloids to highly potent synthetic opioids. However, despite their therapeutic effectiveness, long-standing concerns such as addiction, tolerance, and life-threatening side effects remain major obstacles. This review presents a comprehensive overview of the historical development of narcotics and recent progress in synthetic pain-relief agents. A broad literature survey was conducted, encompassing peer-reviewed articles, clinical trial data, and historical records, complemented by an independent SAR analysis based on the chemical structures of some of the most potent synthetic derivatives reported to date. Key transitions from traditional opioids to synthetic compounds such are explored, alongside novel clinical advancements like Oliceridine (TRV-130), NKTR-181, and Cebranopadol, which demonstrate promising analgesic efficacy with fewer adverse effects. Additionally, recent preclinical studies on synthetic mu-opioid receptor agonists and dual-receptor targeting compounds are discussed for their therapeutic potential. Overall, ongoing research into safer and more effective synthetic opioids offers a hopeful path forward in advancing analgesic therapy.


  • Open Access

    Stability indicating gradient liquid chromatographic technique for the simultaneous estimation of rosiglitazone, glimepiride and metformin HCl in pharmaceutical dosage forms

    by Deepshikha Patle, Manpreet Kaur Deol

    A stability indicating high performance liquid chromatographic method has been developed and validated for the anti-diabetic drugs Rosiglitazone, Glimepiride, and Metformin HCl in pharmaceutical dosage forms. Chromatographic separation was achieved on Zorbex SB C-8 (250 X 4.6 mm) 5µ and Hypersil BDS C18 (200 × 4 mm), 5μ column as stationary phase. Mobile phase consisting of 0.023M potassium dihydrogen phosphate and acetonitrile (60:40, v/v) supplied at a flow rate of 1ml/min. Detection was performed using a SPD-20A prominence UV/VIS detector at 230 nm. The retention time of rosiglitazone, glimepiride and metformin hydrochloride was achieved at 2.4 min, 4.5 min and 5.6 min respectively. The method was validated for linearity, precision, accuracy, toughness, specificity, and forced degradation studies and the relative response factor values of rosiglitazone, glimepiride, and metformin determined from linearity study were 0.998 in the combined form. Rosiglitazone, glimepiride, and metformin HCl showed percentage recoveries of 99.73%, 99.81and 100.31%, respectively. The propesd method found to be very effective and stable for the routine analysis of mentioned antidiabetic drugs in pharmaceutical dosage forms.